Scientific Program

Scientific Program

Full Interactive Program

Slide View Program

The meeting will officially run on Central European Summer Time (CEST), GMT +2.
To convert the meeting times to your local time Click Here

Pdf. version of program. Click here!Mini Program-at-a-Glance. Click here!

Program Highlights

Plenary Sessions

  • How the discovery of antiphospholipid antibodies has changed lupus life
  • When should we use the new drugs in lupus nephritis?
  • Antimalarials are useful but rather weak medications for SLE
  • How common is clinical remission in the real life? Experience from all around the world
  • The time has come to set up diagnostic criteria in SLE?
  • Is it safe to withdraw a low-dose-glucocorticoid in SLE patients in remission?
  • When should targeted therapies be used in the treatment of lupus nephritis?

Parallel Sessions (CORA)

  • Debate: Autoimmunity and autoinflammation
  • Debate: Systemic sclerosis
  • Debate: Rheumatoid arthritis
  • Debate: Systemic sclerosis 2
  • Debate: Spondyolarthritis
  • Dedicated COVID/Vaccination session
  • COVID/Vaccination debate
  • Debate: Sjögren syndrome
  • Debate: Rheumatoid arthritis
  • Debate: Autoimmunity and autoinflammation
  • Debate: Spondyolarthritis
  • Debate: Vasculitis

Live Meet the Professor Sessions (CORA)

  • Jak-inhibitors in rheumatoid arthritis
  • Autoinflammatory diseases
  • Biologics: on and off-label use
  • Cannabis: a friend or a foe?
  • Systemic sclerosis: what is new?

Live Interactive Workshops

  • Lupus nephritis
  • Cutaneous lupus lesions
  • Anti-Rheumatic treatment before and during pregnancy
  • Cardio-pulmonary manifestations
  • Management of lupus pregnancies
  • Cardio-pulmonary manifestations
  • Neuropsychiatric lupus
  • Musculoskeletal manifestations in SLE

Parallel Sessions (LUPUS)

  • Pathogenic insights and implications for treatment
  • Disease activity and outcome measures in SLE
  • NeuroSLE
  • Arthritis, vaccines and COVID-19 in SLE
  • Precision and personalized Medicine
  • Cardiovascular (and vascular) risk management
  • Early SLE
  • Antiphospholipid antibody syndrome and SLE
  • Biomarkers
  • Pipeline molecules in SLE
  • Lupus nephritis – clinical aspects
  • New clues in SLE pathogenesis
  • How do we integrate available biologics in SoC?
  • Skin
  • New clues in LN pathogenesis
  • Difficult-to-manage SLE manifestations
  • Management of SLE: what are we missing?
  • Pregnancy

Live Meet the Professor Sessions (SLE)

  • Biologics in SLE
  • Comorbidities and SLE
  • The standard of care in SLE
  • Molecules in the development in SLE therapy
  • Unmet needs in SLE: how do we assess it?
  • What should we measure in clinical practice in SLE patients?
  • Molecules in the development in SLE therapy
  • The standard of care in SLE
  • Why is everything autoimmune until proven otherwise?